With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance)
demonstrated a statistically significant overall survival benefit from the addition of …

The aim of this study was to characterize the mutational landscape of patients with FLT3-
mutated acute myeloid leukemia (AML) treated within the randomized CALGB …

The randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial (ClinicalTrials. gov
identifier: NCT01757535) evaluated oral azacitidine (Oral-AZA) in patients with acute …

Simple Summary AML is a genetically heterogeneous disease with a median age of
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …

Abstract Purpose of Review This review aims to summarize the pathophysiology, clinical
presentation, and management of acute myeloid leukemia (AML) with FMS-like tyrosine …

Mutations of Nucleophosmin (NPM1) are the most common genetic abnormalities in adult
acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1-mutated AML …

Simple Summary Patients with acute myeloid leukemia (AML) may have a number of
different mutations. Those with mutations in the FLT3 gene have a higher risk of relapse and …

FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid
leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) …